Research study Program year 2021 Source: CMS Open Payments

CIP333 Acetaminophen

Research payments

$869,041

44 payments

Through program year 2021, $869,041 in research payments was reported against CIP333 Acetaminophen, across 44 payments.

Paid by (largest first): Medtronic MiniMed, Inc.; Medtronic, Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

2 rows

Year	Kind	Amount	Payments
2021	Research	$118,614	5
2020	Research	$750,428	39

Breakdown

Who paid Research payments · program years 2020–2021

Medtronic MiniMed, Inc. $750,428 39 payments
Medtronic, Inc. $118,614 5 payments

Who received the money Research payments · program years 2020–2021

Amcr Institute Organisation paid for research $204,355 6 payments
Diablo Clinical Research Organisation paid for research $171,842 7 payments
William Sansum Diabetes Center Organisation paid for research $163,654 6 payments
Rainier Clinical Research Center Organisation paid for research $131,243 9 payments
The Univ. Of Colorado Organisation paid for research $96,063 6 payments
Atlanta Diabetes Associates Organisation paid for research $76,547 8 payments
U Of Co Denverbarbara Davis Center Childhood Diab Organisation paid for research $22,039 1 payment
Rainier Crc, Llc Dba: Rainier Clinical Research Cent Organisation paid for research $3,300 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

6 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.